After analysing the immunohistochemical results, RIPK2 expression was only medium–high in Endometrial cancer (8/12 patients), Lymphoma (6/11 patients) and Prostate cancer (6/12 patients), and the proportion of medium–high expression of RIPK2 in endometrial cancer, lymphoma and prostate cancer tissues was higher than that of low or negative expression (Fig. 2). The gene discussed is RIPK2; the disease is prostate carcinoma.